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Objective: Show relative survivorship associated with speciﬁc disease-causing
mutations of the cystic ﬁbrosis (CF) transmembrane conductance regulator (CFTR).
Methods:We assessed survival effects of CFTR mutations using the CF Foundation
Patient Registry (CFFPR). We estimated hazard ratios corrected for age and sex for
F508del compound heterozygotes relative to homozygotes.
Results: The CFFPR 1986–2011 records data for 44,989 patients; 29,783 have
CFTR mutation information; 48 mutations affect at least 20 patients. There were 9
Class IV or V mutations with better survivorship than F508del: R117H, hazard ratio
(HR) = 0.22, p< 0.001; 2789+5G→A, HR= 0.40, p< 0.001; D1152H, HR= 0.14,
p< 0.001; A455E, HR= 0.36, p= 0.002; 3849+10kbC→T, HR= 0.56, p= 0.002; 5T,
HR< 0.01, p= 0.002; R347H, HR= 0.27, p= 0.009; R117C, HR< 0.01, p= 0.014;
3272−26A→G, HR= 0.24, p= 0.047. Two Class I mutations were more severe
than F508del: Q493X, HR= 1.96, p= 0.007 and 3905insT, HR= 1.79, p= 0.03, and
one Class I mutation was less severe: W1282X, HR= 0.61, p= 0.008. G551D and
I507del had survivorship effects similar to F508del.
Conclusions: With a non-overlapping cohort with more complete genotyping, we
replicated most prior survivorship results [1]. I507del was no longer distinguishable
from F508del; nine other ﬁndings were new: seven mutations were milder and
two were more severe than F508del. Variable courses of disease associated with
mutations of the same class indicate different molecular mechanisms of disease.
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Objectives: Currently almost 8000 people with cystic ﬁbrosis are living in Germany.
Due to medical advances, life expectancy of patients with cystic ﬁbrosis has more
than doubled in recent years. As a result, the aging patients are affected with
diseases of middle age: several of our patients are currently suffering from various
neoplasms. This raises the question if there is a relationship between cystic ﬁbrosis
and cancer disease.
Methods: For this trial, a prospective data collection was used. Data of Patients
with the diagnosis of neoplasm were retrospectively analysed. These data were
compared with the risk of suffering from cancer in the age group between 25 and
49 years. For this purpose, the statistics of the German Cancer Registry were used.
Results: At the time of data analyzation 286 patients were documented in march
2013. Of these, 195 are over 18 yrs and 91 under 18 yrs old. 3 male and 9 female
were diagnosed with cancer. Compared with the general population (0.93%) female
patients with CF between 25 and 49 years of age were more likely to have cancer
with 4.32%. In male patients with CF (2.17%), the incidence rate was higher than
in the general population (0.56%), too.
Conclusion: In this prospective data collection a difference in the incidence of
tumors in patients with CF compared to the general population was evaluated. A
relationship between cystic ﬁbrosis and cancer disease is possible. A Germany-wide
analysis with an enhanced possibility of documentation in the German documenta-
tion system “Muko.dok” and further research is urgently needed. Consequences of
these results could be an earlier routine checkup with the aim of detecting cancer.
